New imaging agent shows promise for kidney cancer detection
NCT ID NCT06840548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new radioactive imaging agent, 68Ga-OncoCAIX, in 20 people with a type of kidney cancer called clear cell renal cell carcinoma. The goal was to see if it is safe and how it spreads in the body. Researchers measured radiation doses to organs and checked for side effects. This is an early-phase study focused on safety and imaging, not treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
IRCCS Ospedale San Raffaele
Milan, Milano, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Immune-Boosting drug combo targets Hard-to-Treat cancers
- New PET scan could spot hidden kidney cancer after treatment
- New drug combo may help save kidneys in High-Risk cancer patients
- New drug combo aims to shrink hard-to-treat tumors
- New drug combo targets Hard-to-Treat cancers in early trial
- Kidney cancer vaccine trial pulled before it began